Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.36 |
| ▸ | SYK | P43405 | 1/20 | 0.36 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | BACE1 | P56817 | 1/20 | 0.33 |
| ▸ | BACE2 | Q9Y5Z0 | 1/20 | 0.33 |
| ▸ | SSTR4 | P31391 | 1/20 | 0.33 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.32 |
| ▸ | MIF | P14174 | 1/20 | 0.32 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.32 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.32 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27211201 | 0.85 | RAB9A (0.40) | KDM4ESYKPDPK1ALDH1A1POLB | |
| SCHEMBL476557 | 0.83 | P4HTM (0.48) | KDM4EALDH1A1NPC1RAB9A | |
| SCHEMBL476517 | 0.83 | P4HTM (0.48) | KDM4EALDH1A1NPC1RAB9A | |
| SCHEMBL21143163 | 0.82 | NR1H2 (0.42) | KDM4ESYKPDPK1ALDH1A1NPC1 | |
| SCHEMBL721864 | 0.80 | TBXAS1 (0.41) | KDM4ESYKPDPK1NPC1MAPT | |
| SCHEMBL721863 | 0.80 | TBXAS1 (0.41) | KDM4ESYKPDPK1NPC1MAPT | |
| SCHEMBL2031522 | 0.80 | SYK (0.38) | KDM4ESYKPDPK1ALDH1A1L3MBTL1 | |
| SCHEMBL13409594 | 0.80 | USP30 (0.34) | KDM4EPDPK1ALDH1A1L3MBTL1POLB | |
| SCHEMBL12742316 | 0.79 | SYK (0.40) | KDM4ESYKPDPK1ALDH1A1L3MBTL1 | |
| SCHEMBL6451838 | 0.79 | SYK (0.36) | SYKPDPK1L3MBTL1SSTR4USP30 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11976057-B2 | MrgX2 antagonists | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2024-05-07 | — | — | US | disclosed |
| CN-117377657-A | Method for preparing pexidasatinib | 庄信万丰股份有限公司 | 2024-01-09 | — | — | CN | disclosed |
| CN-116390917-A | MRGX2 antagonists | 葛兰素史密斯克莱知识产权发展有限公司 | 2023-07-04 | — | — | CN | disclosed |
| US-20230131535-A1 | ARYLMETHYLENE AROMATIC COMPOUNDS AS Kv1.3 POTASSIUM SHAKER CHANNEL BLOCKERS | D. E. SHAW RESEARCH, LLC | 2023-04-27 | — | — | US | disclosed |
| US-20230131535-A1 | ARYLMETHYLENE AROMATIC COMPOUNDS AS Kv1.3 POTASSIUM SHAKER CHANNEL BLOCKERS | D. E. SHAW RESEARCH, LLC | 2023-04-27 | — | — | US | disclosed |
| US-20230131535-A1 | ARYLMETHYLENE AROMATIC COMPOUNDS AS Kv1.3 POTASSIUM SHAKER CHANNEL BLOCKERS | D. E. SHAW RESEARCH, LLC | 2023-04-27 | — | — | US | disclosed |
| EP-3581573-B1 | SYNTHESIS OF A COMPOUND THAT MODULATES KINASES | PLEXXIKON INC (US) | 2022-07-06 | — | — | EP | disclosed |
| US-20220112174-A1 | MRGX2 ANTAGONISTS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2022-04-14 | — | — | US | disclosed |
| WO-2021071821-A1 | ARYLMETHYLENE AROMATIC COMPOUNDS AS KV1.3 POTASSIUM SHAKER CHANNEL BLOCKERS | D.E. SHAW RESEARCH, LLC (US) | 2021-04-15 | — | — | WO | disclosed |
| US-10730876-B2 | Synthesis of a compound that modulates kinases | PLEXXIKON INC. (US) | 2020-08-04 | — | — | US | disclosed |
| US-20160326169-A1 | SYNTHESIS OF A COMPOUND THAT MODULATES KINASES | DAIICHI SANKYO, INC. | 2016-11-10 | — | — | US | disclosed |
| US-9096593-B2 | Compounds and methods for kinase modulation, and indications therefor | PLEXXIKON INC. (US) | 2015-08-04 | — | — | US | disclosed |
| US-9096593-B2 | Compounds and methods for kinase modulation, and indications therefor | PLEXXIKON INC. (US) | 2015-08-04 | — | — | US | disclosed |
| US-20140045840-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC. (US) | 2014-02-13 | — | — | US | disclosed |
| US-20140045840-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC. (US) | 2014-02-13 | — | — | US | disclosed |
| WO-2011057022-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON, INC. (US) | 2011-05-12 | — | — | WO | disclosed |
| EP-1534700-A1 | NOVEL THIOPHENE DERIVATIVES, PREPARATION METHOD THEREOF AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME | WARNER-LAMBERT COMPANY LLC (US) | 2005-06-01 | — | — | EP | disclosed |
| US-20040072871-A1 | Novel thiophene derivatives, their process of preparation and the pharmaceutical compositions which comprise them | WARNER-LAMBERT COMPANY LLC | 2004-04-15 | — | — | US | disclosed |
| WO-2004018448-A1 | NOVEL THIOPHENE DERIVATIVES, PREPARATION METHOD THEREOF AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME | WARNER-LAMBERT COMPANY LLC (US) | 2004-03-04 | — | — | WO | disclosed |
| EP-1394159-A1 | New thiophene derivatives, process for their preparation and pharmaceutical compositions containing them | Warner-Lambert Company LLC (US) | 2004-03-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10730876-B2 | Synthesis of a compound that modulates kinases | FLT3, KIT, MAP3K1 | KDM4E 1453/4885SYK 239/4885PDPK1 135/4885 |
| US-11976057-B2 | MrgX2 antagonists | MRGPRX2, MRGPRX1, MRGPRX4 | KDM4E 2811/4885SYK 4865/4885PDPK1 3525/4885 |
| US-20140045840-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | KIT, FLT3, BRAF | KDM4E 2135/4885SYK 52/4885PDPK1 296/4885 |
| US-20160326169-A1 | SYNTHESIS OF A COMPOUND THAT MODULATES KINASES | FLT3, KIT, MAP3K1 | KDM4E 1453/4885SYK 239/4885PDPK1 135/4885 |
| US-20040072871-A1 | Novel thiophene derivatives, their process of preparation and the pharmaceutical compositions which comprise them | MMP11, MMP13, CBR1 | KDM4E 2797/4885SYK 4162/4885PDPK1 4797/4885 |
| US-20220112174-A1 | MRGX2 ANTAGONISTS | MRGPRX2, MRGPRX1, MRGPRX4 | KDM4E 2811/4885SYK 4865/4885PDPK1 3525/4885 |
| US-20230131535-A1 | ARYLMETHYLENE AROMATIC COMPOUNDS AS Kv1.3 POTASSIUM SHAKER CHANNEL BLOCKERS | KCNJ2, KCNA3, KCNK3 | KDM4E 217/4885SYK 840/4885PDPK1 462/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.